HC Wainwright & Co. Downgrades KalVista Pharmaceuticals to Neutral, Lowers Price Target to $27

Benzinga Newsdesk www.benzinga.com Negative 93.4%

Neg 93.4% Neu 0% Pos 0%

HC Wainwright & Co. analyst Andrew S. Fein downgrades KalVista Pharmaceuticals (NASDAQ:KALV) from Buy to Neutral and lowers the price target from $37 to $27.